News

Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX ...
Intel is cutting costs and restructuring amid weak margins and mixed Q2 results, with long-term upside tied to AI. Find out ...
Ether’s bullish outlook strengthens as Bitcoin dominance falls below 60%, its lowest since February. Analysts say Ether is ...
The company reported an adjusted loss of 42 cents per share, wider than Wall Street's projected 12-cent loss, according to ...